The ANSWER (long-term albumin administration in decompensated cirrhosis) study has shown that treatment with human albumin improves survival and prevents the occurrence of major complications in patients with cirrhosis and ascites. This online course discusses results of the cost-effectiveness analysis of the ANSWER study, delivered by the principal investigators, Professor Mauro Bernardi and Associate Professor Paolo Caraceni from the University of Bologna, Italy. In his presentation, Professor Bernardi talks about the burden of liver cirrhosis and its impact on mortality, morbidity, and healthcare costs. Professor Caraceni shares findings of the economic analysis and cost-effectiveness data of the ANSWER study.
Professor Mauro Bernardi, Professor of Internal Medicine at the Alma Mater Studiorum,the University of Bologna
Dr Paolo Caraceni is the Associate Professor of Internal Medicine at the Department of Medical and Surgical Sciences, University of Bologna
Please watch the video before attempting the assessment questions.
Terms & Conditions:
■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point.
■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points
To play this video, you are required to have a media player such as Windows Media Player (PC), QuickTime (MAC) or another third party media player.